Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?
Abstract
:1. Introduction
2. Adapting Treatments for Elderly Patients
3. Continuous Treatments Improve Progression-Free Survival
4. Best Overall Survival So Far Achieved with Continuous Treatments
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Howlader, N.; Noone, A.M.; Krapcho, M.; Miller, D.; Brest, A.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.R.; et al. SEER Cancer Statistics Review, 1975–2018; based on November 2020 SEER data submission, posted to the SEER web site; National Cancer Institute: Bethesda, MD, USA. Available online: https://seer.cancer.gov/csr/1975_2018/ (accessed on 15 April 2021).
- Wildes, T.M.; Rosko, A.; Tuchman, S.A. Multiple myeloma in the older adult: Better prospects, more challenges. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 2531–2540. [Google Scholar] [CrossRef] [PubMed]
- Muhlbacher, A.C.; Nubling, M. Analysis of physicians’ perspectives versus patients’ preferences: Direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur. J. Health Econ. 2011, 12, 193–203. [Google Scholar] [CrossRef]
- Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; et al. Frailty in older adults: Evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 2001, 56, M146–M156. [Google Scholar] [CrossRef] [PubMed]
- Rockwood, K.; Mitnitski, A. Frailty in relation to the accumulation of deficits. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62, 722–727. [Google Scholar] [CrossRef] [PubMed]
- Martinez-Tapia, C.; Canoui-Poitrine, F.; Bastuji-Garin, S.; Soubeyran, P.; Mathoulin-Pelissier, S.; Tournigand, C.; Paillaud, E.; Laurent, M.; Audureau, E.; ELCAPA Study Group. Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version. Oncologist 2016, 21, 188–195. [Google Scholar] [CrossRef] [PubMed]
- Cook, G.; Larocca, A.; Facon, T.; Zweegman, S.; Engelhardt, M. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia 2020, 34, 2285–2294. [Google Scholar] [CrossRef]
- Isaacs, A.; Fiala, M.; Tuchman, S.; Wildes, T.M. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. J. Geriatr. Oncol. 2020, 11, 311–315. [Google Scholar] [CrossRef]
- Palumbo, A.; Bringhen, S.; Mateos, M.-V.; Larocca, A.; Facon, T.; Kumar, S.K.; Offidani, M.; McCarthy, P.; Evangelista, A.; Lonial, S.; et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report. Blood 2015, 125, 2068–2074. [Google Scholar] [CrossRef] [PubMed]
- Perrot, A.; Facon, T.; Plesner, T.; Usmani, S.Z.; Kumar, S.; Bahlis, N.J.; Hulin, C.; Orlowski, R.Z.; Nahi, H.; Mollee, P.; et al. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 227–237. [Google Scholar] [CrossRef] [PubMed]
- Rajkumar, S.V.; Blood, E.; Vesole, D.; Fonseca, R.; Greipp, P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006, 24, 431–436. [Google Scholar] [CrossRef] [PubMed]
- Facon, T.; Mary, J.-Y.; Pégourie, B.; Attal, M.; Renaud, M.; Sadoun, A.; Voillat, L.; Dorvaux, V.; Hulin, C.; Lepeu, G.; et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006, 107, 1292–1298. [Google Scholar] [CrossRef]
- Larocca, A.; Bonello, F.; Gaidano, G.; D’agostino, M.; Offidani, M.; Cascavilla, N.; Capra, A.; Benevolo, G.; Tosi, P.; Galli, M.; et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021, 137, 3027–3036. [Google Scholar] [CrossRef]
- Hulin, C.; Belch, A.; Shustik, C.; Petrucci, M.T.; Dührsen, U.; Lu, J.; Song, K.; Rodon, P.; Pégourié, B.; Garderet, L.; et al. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016, 34, 3609–3617. [Google Scholar] [CrossRef] [PubMed]
- Facon, T.; Kumar, S.; Plesner, T.; Orlowski, R.Z.; Moreau, P.; Bahlis, N.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N. Engl. J. Med. 2019, 380, 2104–2115. [Google Scholar] [CrossRef] [PubMed]
- Facon, T.; Kumar, S.K.; Plesner, T.; Orlowski, R.Z.; Moreau, P.; Bahlis, N.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 1582–1596. [Google Scholar] [CrossRef]
- San-Miguel, J.; Avet-Loiseau, H.; Paiva, B.; Kumar, S.K.; Dimopoulos, M.A.; Facon, T.; Mateos, M.-V.; Touzeau, C.; Jakubowiak, A.J.; Usmani, S.Z.; et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 2022, 139, 492–501. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Manier, S.; Facon, T. Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment? Hemato 2024, 5, 115-118. https://doi.org/10.3390/hemato5020010
Manier S, Facon T. Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment? Hemato. 2024; 5(2):115-118. https://doi.org/10.3390/hemato5020010
Chicago/Turabian StyleManier, Salomon, and Thierry Facon. 2024. "Elderly Patients with Newly Diagnosed Multiple Myeloma: Continuous or Fixed Duration Treatment?" Hemato 5, no. 2: 115-118. https://doi.org/10.3390/hemato5020010